Joshua D. Cohen; Ammar A. Javed; Christopher J. Thoburn; Fay Wong; Jeanne Tie; Peter Gibbs; C. Max Schmidt; Michele Yip-Schneider; Peter J. Allen; Mark Schattner; Randall E. Brand; Aatur D. Singhi; Gloria M. Petersen; Seung‐Mo Hong; Song Cheol Kim; Massimo Falconi; Claudio Doglioni; Matthew J. Weiss; Nita Ahuja; Jin He; Martin A. Makary; Anirban Maitra; Samir Hanash; Marco Dal Molin; Yuxuan Wang; Lu Li; Janine Ptak; Lisa Dobbyn; Joy Schaefer; Natalie Silliman; Maria Popoli; Michael Goggins; Ralph H. Hruban; Christopher L. Wolfgang; Alison P. Klein; Cristian Tomasetti; Nickolas Papadopoulos; Kenneth W. Kinzler; Bert Vogelstein; Anne Marie Lennon · 2017 · Proceedings of the National Academy of Sciences
Paper
Significance Few patients with pancreatic cancer survive longer than 5 y, in part because most patients are identified only after their disease has progressed to an advanced stage. In this study, we show how combining mutations in circulating tumor DNA (ctDNA) with protein markers can result in a screening test with improved sensitivity while retaining specificity. The combination of the ctDNA and protein markers was superior to any single marker. Moreover, the combination detected nearly two-thirds of pancreatic cancers that had no evidence of distant metastasis at the time of surgical resection. The strategy may represent an approach to detect cancers of many types at an earlier stage.
Analysis
This study proposes a liquid biopsy strategy combining circulating tumor DNA (ctDNA) mutations and protein markers to improve the early detection of pancreatic cancer, a disease with low survival rates due to late diagnosis.
Discovery
Naveed Shuja
Dr. Erhan OKTAY
Michaela Kuhlen; Maximilian Schmut; Markus Metzle; R. Claus
Noriyoshi Sawabata
Aarchi Singh Thakur; Abhijoy Sarkar
Faeze Shahraki; Azadeh Meshkini; Elham Nazari
Source record